胃印戒细胞癌的临床病理特征与外科综合治疗
Gastric signet ring cell carcinoma: clinicopathology and surgical treatment combined with comprehensive therapy
梅郁, 朱正纲 . 胃印戒细胞癌的临床病理特征与外科综合治疗[J]. 外科理论与实践, 2021 , 26(01) : 79 -83 . DOI: 10.16139/j.1007-9610.2021.01.017
| [1] | Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. |
| [2] | Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. |
| [3] | Flejou JF. WHO classification of digestive tumors: the fourth edition[J]. Ann Pathol, 2011, 31(5 Suppl):S27-S31. |
| [4] | Taghavi S, Jayarajan SN, Davey A, et al. Prognostic significance of signet ring gastric cancer[J]. J Clin Oncol, 2012, 30(28):3493-3498. |
| [5] | Chon HJ, Hyung WJ, Kim C, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia[J]. Ann Surg, 2017, 265(5):946-953. |
| [6] | Kao YC, Fang WL, Wang RF, et al. Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer[J]. Gastric Cancer, 2019, 22(2):255-263. |
| [7] | Jiang CG, Wang ZN, Sun Z, et al. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study[J]. J Surg Oncol, 2011, 103(7):700-703. |
| [8] | Li C, Kim S, Lai JF, et al. Advanced gastric carcinoma with signet ring cell histology[J]. Oncology, 2007, 72(1-2):64-68. |
| [9] | Kang SH, Kim JS, Moon HS, et al. Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment rea-lly risky?[J]. Medicine, 2017, 96(33):e7532. |
| [10] | Pyo JH, Shin CM, Lee H, et al. A risk-prediction model based on lymph-node metastasis for incorporation into a treatment algorithm for signet ring cell-type intramucosal gastric cancer[J]. Ann Surg, 2016, 264(6):1038-1043. |
| [11] | Lee IS, Lee S, Park YS, et al. Applicability of endoscopic submucosal dissection for undifferentiated early gastric cancer: mixed histology of poorly differentiated adenocarcinoma and signet ring cell carcinoma is a worse predictive factor of nodal metastasis[J]. Surg Oncol, 2017, 26(1):8-12. |
| [12] | Zhao X, Cai A, Xi H, et al. Predictive factors for lymph node metastasis in early gastric cancer with signet ring cell histology: a meta-analysis[J]. ANZ J Surg, 2017, 87(12):981-986. |
| [13] | Chu YN, Mao T, Li XY, et al. Predictors of lymph node metastasis and differences between pure and mixed histologic types of early gastric signet-ring cell carcinomas[J]. Am J Surg Pathol, 2020, 44(7):934-942. |
| [14] | Abe S, Oda I, Suzuki H, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undiffe-rentiated early gastric cancer[J]. Endoscopy, 2013, 45(9):703-707. |
| [15] | Kim MN, Kim HK, Shim CN, et al. Tumour size is rela-ted to the curability of signet ring cell early gastric cancer with endoscopic submucosal dissection: a retrospective single centre study[J]. Dig Liver Dis, 2014, 46(10):898-902. |
| [16] | Lee YM, Kang SH, Kim JS, et al. Subepithelial spread of early gastric signet ring cell carcinoma: how far they can reach?[J]. Dig Dis, 2020, 38(6):442-448. |
| [17] | Qi J, Zhang P, Wang Y, et al. Does total gastrectomy provide better outcomes than distal subtotal gastrectomy for distal gastric cancer? a systematic review and meta-analysis[J]. PloS One, 2016, 11(10):e0165179. |
| [18] | Arer IM, Yabanoglu H, Akdur A, et al. Total versus subtotal gastrectomy for signet ring cell carcinoma of the stomach[J]. J Coll Physicians Surg Pak, 2017, 27(10):616-620. |
| [19] | de Manzoni G, Verlato G, Bencivenga M, et al. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer[J]. Eur J Surg Oncol, 2015, 41(4):534-540. |
| [20] | Chen L, Shi Y, Yuan J, et al. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients[J]. Med Oncol, 2014, 31(9):159-169. |
| [21] | Shu Y, Zhang W, Hou Q, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer[J]. Nat Commun, 2018, 9(1):2447-2457. |
| [22] | Heger U, Sisic L, Nienhuser H, et al. Neoadjuvant therapy improves outcomes in locally advanced signet-ring-cell containing esophagogastric adenocarcinomas[J]. Ann Surg Oncol, 2018, 25(8):2418-2427. |
| [23] | Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study[J]. Ann Surg, 2011, 254(5):684-693. |
| [24] | Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?[J]. Ann Surg Oncol, 2014, 21(5):1739-1748. |
| [25] | Kim S, Fiteni F, Paget-Bailly S, et al. The impact of taxa-ne-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas[J]. J Hematol Oncol, 2015, 8:52. |
| [26] | Li Y, Ma FH, Xue LY, et al. Neoadjuvant chemotherapy vs. upfront surgery for gastric signet ring cell carcinoma: a retrospective, propensity score-matched study[J]. World J Gastroenterol, 2020, 26(8):818-827. |
| [27] | Charalampakis N, Nogueras Gonzalez GM, Elimova E, et al. The proportion of signet ring cell component in patients with localized gastric adenocarcinoma correlates with the degree of response to pre-operative chemoradiation[J]. Oncology, 2016, 90(5):239-247. |
| [28] | Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol, 2012, 30(19):2327-2333. |
| [29] | Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33(28):3130-3136. |
| [30] | Wei F, Lyu H, Wang S, et al. Postoperative radiotherapy improves survival in gastric signet-ring cell carcinoma: a SEER database analysis[J]. J Gastric Cancer, 2019, 19(4):393-407. |
| [31] | Lemoine N, Adenis A, Bouche O, et al. Signet ring cells and efficacy of first-line chemotherapy in advanced gastric or oesogastric junction adenocarcinoma[J]. Anticancer Res, 2016, 36(10):5543-5549. |
| [32] | Mariette C, Bruyere E, Messager M, et al. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?[J]. Ann Surg Oncol, 2013, 20(4):1240-1249. |
| [33] | Pernot S, Dubreuil O, Aparicio T, et al. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study[J]. Br J Cancer, 2018, 119(4):424-428. |
| [34] | Badgwell B, Blum M, Das P, et al. Phase Ⅱ trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma[J]. Ann Surg Oncol, 2017, 24(11):3338-3344 |
| [35] | Hotopp T. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?[J]. Surg Oncol, 2019, 28:159-166. |
/
| 〈 |
|
〉 |
